ISDA

Entry Detail

PDB ID:

7WKX

Keywords:

CYTOKINE

Title:

IL-17A in complex with the humanized antibody HB0017

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Cricetulus griseus

PDB Version:

Deposition Date:

2022-01-12

Release Date:

2022-03-23

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.81 Å

R-Value Free:

0.25

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Polymer Type:polypeptide(L)
Description:Heavy chain of HB0017 Fab
Chain IDs:A, B
Chain Length:217
Number of Molecules:2
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Description:Light chain of HB0017 Fab
Chain IDs:C, D
Chain Length:219
Number of Molecules:2
Biological Source:Homo sapiens

Protein Blast

Polymer Type:polypeptide(L)
Description:Interleukin-17A
Chain IDs:E, F
Chain Length:151
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q16552 Pfam ID:PF06083

Ligand Molecules

ACY

MLA

Primary Citation

Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseases.

Xu, J.G, Jia, H, Chen, S, Xu, J, Zhan, Y, Yu, H, Wang, W, Kang, X, Cui, X, Feng, Y, Chen, X, Xu, W, Pan, X, Wei, X, Li, H, Wang, Y, Xia, S, Liu, X, Yang, L, He, Y, Zhu, X.Show

Int.J.Biol.Macromol. 202 529 538 (2022)

PMID: 35066019 DOI: 10.1016/j.ijbiomac.2022.01.119

Abstact

The pro-inflammatory cytokine interleukin-17A (IL-17A) is a key driver of multiple inflammatory and immune disorders. Therapeutic antibodies targeting IL-17A have been proven effective in treating patients with these diseases; however, large variations in clinical outcomes have been observed with different antibodies. In this study, we developed HB0017, a novel monoclonal antibody that targets human IL-17A. HB0017 specifically and strongly bound to human, cynomolgus monkey, and mouse IL-17A at the physiological interface with the IL-17A receptor. In human and monkey cells, HB0017 potently antagonized the functions of IL-17A through competitive binding. HB0017 functioned equivalently to that of clinically approved antibodies in terms of therapeutic efficacy for inflammatory disorders and psoriasis in a mouse model. The results indicate that HB0017 may be an alternative biological therapy for treating patients with inflammation and autoimmune diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures